United Therapeutics (NASDAQ: UTHR)‘s stock had its “hold” rating restated by analysts at Deutsche Bank in a research report issued to clients and investors on Wednesday. They currently have a $56.00 price target on the stock, up from their previous price target of $52.00.
The analysts wrote, “We are raising our TP to $56 from $52 current. Maintain HOLD. We are raising our TP to $56 as we cut our expense numbers in out years to keep them in-line with significant sales erosion beginning 2017 & since we are not modeling Oral Remodulin sales. We continue to remain on sidelines as we seek more clarity on 1) Commercial OPP’Y for Oral Remodulin and 2) Patent issues with Sandoz.”
UTHR has been the subject of a number of other recent research reports. Analysts at RBC Capital raised their price target on shares of United Therapeutics from $45.00 to $50.00 in a research note to investors on Wednesday. They now have a “sector perform” rating on the stock. Separately, analysts at Brean Murray downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating in a research note to investors on Tuesday. Finally, analysts at Ladenburg Thalmann raised their price target on shares of United Therapeutics from $59.00 to $69.00 in a research note to investors on Tuesday, February 19th.
Four analysts have rated the stock with a buy rating, seven have issued a hold rating, and two have issued a sell rating to the stock. The stock has an average rating of “hold” and an average price target of $53.25.
Shares of United Therapeutics traded down 0.10% during mid-day trading on Wednesday, hitting $58.14. United Therapeutics has a 52 week low of $40.34 and a 52 week high of $59.00. The stock’s 50-day moving average is currently $54.05. The company has a market cap of $2.954 billion and a P/E ratio of 11.69.
United Therapeutics last posted its quarterly earnings results on Tuesday, February 26th. The company reported $1.65 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.25 by $0.40. The company had revenue of $243.82 million for the quarter, compared to the consensus estimate of $233.41 million. During the same quarter in the prior year, the company posted $0.77 earnings per share. The company’s quarterly revenue was up 24.9% on a year-over-year basis. Analysts expect that United Therapeutics will post $5.65 EPS for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
